Announcement of TTY Biopharm's unaudited income information in March 2026
2026.4.9
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2026/04/09 | Time of announcement | 16:47:37 |
| Subject | Announcement of TTY Biopharm's unaudited income information in March 2026 | ||||
| Date of events | 2026/04/09 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2026/04/09 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $599,723 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $235,726 thousands, and a consolidated income before tax of $294,311 thousands in March 2026; net income attributed to stockholders of the company was $231,782 thousands; EPS is $0.93. Year-to-date consolidated net sales was $1,520,487 thousands (in NT dollars; unaudited), a consolidated operating profit was $489,471 thousands and consolidated income before tax was $573,619 thousands until March 2026; year-to-date net income attributed to stockholders of the company was $443,065 thousands; EPS is $1.78. 6.Countermeasures:None. 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. |
||||